Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial.
Saved in:
| Title: | Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial. |
|---|---|
| Authors: | Bilen MA; Winship Cancer Institute of Emory University, Atlanta, GA, USA. Mehmet.a.bilen@emory.edu.; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. Mehmet.a.bilen@emory.edu., Vo BT; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Liu Y; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Greenwald R; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Davarpanah AH; Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA., McGuire D; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.; Emory Vaccine Center, Emory University, Atlanta, GA, USA., Shiradkar R; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA., Li L; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA., Midya A; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA., Nazha B; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Brown JT; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Williams S; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Session W; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Russler G; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Caulfield S; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Pharmaceutical Services, Emory University School of Medicine, Atlanta, GA, USA., Joshi SS; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Narayan VM; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Filson CP; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Ogan K; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Kucuk O; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Carthon BC; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Del Balzo L; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Cohen A; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Boyanton A; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Prokhnevska N; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Cardenas MA; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Sobierajska E; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Jansen CS; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Patil DH; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Nicaise E; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Osunkoya AO; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.; Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA., Kissick HT; Winship Cancer Institute of Emory University, Atlanta, GA, USA. haydn.kissick@emory.edu.; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA. haydn.kissick@emory.edu.; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA. haydn.kissick@emory.edu.; Emory Vaccine Center, Emory University, Atlanta, GA, USA. haydn.kissick@emory.edu., Master VA; Winship Cancer Institute of Emory University, Atlanta, GA, USA. vmaster@emory.edu.; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA. vmaster@emory.edu. |
| Source: | Nature cancer [Nat Cancer] 2025 Mar; Vol. 6 (3), pp. 432-444. Date of Electronic Publication: 2025 Feb 27. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
